Champions Oncology, Inc. — Form 10-Q Summary
Business context and period: The company develops TumorGraft-based personalized cancer-care and drug-development services. Its Personalized Oncology Solutions (POS) serves physicians and patients; Translational Oncology Solutions (TOS) serves pharmaceutical and biotechnology companies. This filing covers the quarter and nine months ended January 31, 2013, compared with the same periods in 2012. Amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Quarter ended Jan. 31, 2013 | Quarter ended Jan. 31, 2012 | Nine months ended Jan. 31, 2013 | Nine months ended Jan. 31, 2012 |
|---|---|---|---|---|
| Revenue | $2.917 million | $2.396 million | $6.481 million | $5.768 million |
| Operating loss | $(0.720) million | $(1.773) million | $(4.235) million | $(6.463) million |
| Net loss | $(0.990) million | $(1.719) million | $(4.284) million | $(6.111) million |
| Net loss per share, basic and diluted | $(0.02) | $(0.04) | $(0.09) | $(0.13) |
- Quarterly revenue increased 21%; nine-month revenue increased 14%. Quarterly POS revenue fell 29% to $473,000, while TOS revenue rose 41% to $2.444 million. Nine-month POS revenue was $1.850 million, up 6%, and TOS revenue was $4.631 million, up 18%.
- POS gross margin was negative 40% for the quarter and negative 5% for the nine months, versus 29% and 17% in the corresponding 2012 periods. TOS gross margin improved to 75% and 63%, respectively, from 53% and 51%.
- Nine-month operating cash use was $3.132 million, compared with $3.704 million a year earlier. Investing cash use was $35,000; financing provided $9.195 million, principally from the January 2013 private placement.
- At January 31, cash and cash equivalents were $10.769 million, working capital was approximately $9 million, and total current liabilities were $2.684 million. The company reported no conventional debt. Total liabilities were $3.677 million, including a $993,000 warrant liability. Stockholders’ deficit was $7.601 million; redeemable common stock was recorded separately at $16.936 million.
Material changes and unusual items
- On January 28, 2013, the company sold 18.6 million shares at $0.50 per share for gross proceeds of $9.3 million and issued warrants to buy 1.86 million shares at $0.66. The shares are classified as temporary equity because investors may require cash redemption upon specified change-of-control or asset-sale events. The financing also triggered anti-dilution issuance of 1,064,658 additional shares to April 2011 investors.
- TOS revenue included an $880,000 one-time Cephalon payment recognized in the quarter and nine-month period. In exchange, Cephalon gave up future milestone and royalty payments on one compound; the other compound remained under evaluation. No milestones had been achieved.
- Operating expenses declined overall. Nine-month research and development expense fell 44% to $1.415 million, and general and administrative expense fell 21% to $3.484 million; sales and marketing expense rose 9% to $2.047 million. Management attributed reductions partly to lower laboratory and tumor-procurement costs and lower stock-based compensation and consulting costs.
- The company’s POS strategy emphasizes increasing implant and study volumes, including lower pricing to broaden access and build its TumorBank. Quarterly implants increased 64% and completed patient studies increased 160% year over year, while POS revenue per implant and study declined. Management said laboratory work had been moved in-house to reduce future service costs and was evaluating capacity needs.
Outlook, risks, and contingencies
- Management stated that cash on hand at January 31 was adequate to fund operations at least through fiscal 2014. No formal revenue, earnings, or cash-flow guidance was provided. Management cautioned that additional capital, if needed, might not be available on acceptable terms or at all.
- The redemption features of both private placements, warrant exercise-price reset provisions, and future-financing participation rights could affect liquidity, equity classification, and dilution. Warrant fair-value changes are noncash but affect reported earnings; the quarter included $255,000 of warrant-related expense.
- Registration-rights defaults could trigger cash penalties; potential penalties were not accrued because management did not consider them probable. The filing describes potential penalties of $50,000 to $130,000 for each 30-day default period, subject to contractual limits.
- The Irinophore C license carries an accrued annual royalty of C$10,000, possible development milestones of up to $3 million, and potential commercialization royalties and sales milestones. Cephalon’s remaining compound also has potential milestone and royalty economics.
- Management reported no material litigation exposure, no material changes to previously disclosed risk factors, and effective disclosure controls. The filing identifies foreign-exchange exposure and dependence on future business performance and available financing among relevant uncertainties.
Important facts for investors to verify
- Whether POS volume growth and the in-house laboratory transition improve POS unit economics and margins despite lower pricing.
- How much of TOS growth is recurring versus attributable to the one-time $880,000 Cephalon payment, and the status of the remaining compound.
- Cash burn and runway relative to management’s fiscal 2014 estimate, including any subsequent financing needs.
- The scope and potential liquidity effect of private-placement redemption rights, warrant resets, registration obligations, and future dilution.
- Outstanding share counts and potential dilution: 66,752,100 common shares were reported outstanding as of February 28, 2013; the filing also lists 18,370,622 potential common-stock equivalents as of January 31, 2013.